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Background: The prevalence of maternal oral contraceptive pills (OCP) use and that of childhood asthma
are high in western countries. The aim of this study is to examine the association of OCP use with
childhood wheeze and allergic diseases in Japan.
Methods: Relevant data were extracted from a hospital based birth cohort study named as Tokyo-Chil-
dren's Health, Illness and Development Study (T-CHILD) of which questionnaire conducted during
pregnancy included maternal history and duration of OCP use. To identify wheeze and allergic diseases in
the children, the questionnaire of the International Study of Asthma and Allergies in Childhood (ISAAC)
was used. Logistic regression models were applied to estimate those association and adjustments were
made for maternal history of allergy, maternal education level, maternal age at pregnancy, maternal BMI,
maternal smoking during pregnancy, mode of delivery, gestational age at delivery, daycare attendance,
number of previous live births, and gender of child.
Results: OCP use was associated with ever wheeze (adjusted odds ratio [aOR], 1.62; 95% conﬁdence in-
terval [CI], 1.10e2.40), current wheeze (aOR, 1.59; 95% CI, 1.01e2.50), ever asthma (aOR, 1.65; 95% CI, 1.02
e2.65), and ever rhinitis (aOR, 1.90; 95% CI, 1.30e2.80). Compared with no prior OCP use, using OCP for
more than three months statistically increased the odds of ever wheeze (P ¼ 0.012), current wheeze
(P ¼ 0.035), and ever rhinitis (P ¼ 0.002).
Conclusions: Our ﬁndings suggest that maternal OCP use has a role in the development of wheeze,
asthma and rhinitis in children. Extended use of OCP is likely to increase the risk of wheeze and rhinitis.
Copyright © 2016, Japanese Society of Allergology. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
First wave of allergic epidemic occurred in westernized coun-
tries including Japan drew attention mainly on asthma and its
prevalence has reached high plateau in recent decades,1 followed
by second wave from developing countries. Although Japan has
been a top runner of this undesirable race in the Asia-Paciﬁc region,
now prevalence of allergic diseases such as asthma, atopic eczema,
and rhinoconjunctivitis among young schoolchildren have becomeDepartment of Medical
onment and Children's Study
evelopment, 2-10-1, Okura,
ety of Allergology.
rgology. Production and hosting by Elsehigh in many countries in this region.2,3 Environmental changes
elicited by rapid industrialization and afﬂuent life might have
interacted genetic function resulting in the epidemic of asthma and
allergic diseases.4
The emerging concept of Developmental Origins of Health and
Disease (DOHaD) hypothesis suggests that various environmental
exposures during preconceptional and postconceptional period for
embryo and fetus may contribute to development of non-
communicable diseases for children.5,6 The cause and develop-
ment of allergy are complicated and need further investigation.
In western afﬂuent countries, oral contraceptive pills (OCP) use
has become common and an association of OCP use with childhood
wheeze and asthma was reported in several studies from western
countries, although conclusions were mixed.7e9 The aim of our
study was to elucidate the relationship between OCP use andvier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
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region of western countries.
We examined whether a history of maternal OCP use and the
duration of the usage before pregnancy were associated with
wheeze and allergic features in ﬁve-year-old children.Methods
Study design was a hospital based prospective birth cohort
study, which was named as Tokyo-Children's Health, Illness and
Development study (T-CHILD study).10,11 We recruited 1701 preg-
nant women at the ﬁrst antenatal visit at the National Center for
Child Health and Development (NCCHD) in Tokyo Japan between
2003 and 2005. Among neonates born from these women, a total of
1550 newborn babies and their mothers were registered in this
cohort from March 2004 to August 2006. Baseline data were
collected from questionnaires answered by mothers during preg-
nancy and their medical charts. Outcome data of children at 5 years
old were obtained from the International Study of Asthma and
Allergies in Childhood (ISAAC) questionnaire which was translated
into Japanese and validated through the process of back translation
under cooperation of the sterling committee members. The deﬁ-
nitions of outcomes and exposures are described in Table 1. Po-
tential confounders were maternal history of allergy (asthma,
atopic dermatitis, or allergic rhinitis), maternal education level,
maternal age at delivery, maternal body mass index (BMI) at
recruitment, maternal smoking during pregnancy, caesarean sec-
tion, gestational age at delivery, number of previous live births,
daycare attendance at age of one and gender.Table 1
Deﬁnitions of outcomes and exposures.
Outcomes of children at ﬁve years old
Wheeze ever a positive answer to the question at ﬁve years old of
the children: “Has your child ever had wheezing or
whistling in the chest at any time in the past?”
Wheeze current a positive answer to the question at ﬁve years old of
the children: “Has your child ever had wheezing or
whistling in the past 12 months?”
Asthma ever a positive answer to the question at ﬁve years old of
the children: “Have you ever had asthma?”
Asthma current a positive answer to the question at ﬁve years old of
the children: “Has your child ever been diagnosed
by a doctor as having asthma in the past 12
months?”
Rhinitis ever a positive answer to the question at ﬁve years old of
the children: “Has your child ever had a problem
with sneezing, or a runny, or blocked nose when he/
she DID NOT have a cold or the ﬂu?”
Rhinitis current a positive answer to the question at ﬁve years old of
the children: “In the past 12 months, has your child
had a problemwith sneezing, or a runny, or blocked
nose when he/she DID NOT have a cold or the ﬂu?”
Eczema ever a positive answer to the question at ﬁve years old of
the children: “Have your child ever had eczema?”
Eczema current a positive answer to the question at ﬁve years old of
the children: “Has your child had this itchy rash at
any time in the past 12months?” and “Has this itchy
rash at any time affected any of the following
places: the folds of the elbows, behind the knees, in
front of the ankles, under the buttocks, or around
the neck, ears or eyes?”
Exposures of COP
Past history of OCP use a positive answer to the question of the base line
data, “Have you ever used the pill?”.
Duration of OCP use a positive answer to the question of the base line
data, “How long have you ever used the pill totally?”
and it was classiﬁed into three groups, (not use, OCP
1e6 months use and OCP >6 months use).Data from surveys conducted at pregnancy and children at age
of ﬁve were used for analysis of the current study. Data of Twins
and those with missing values were not included for analysis.
For statistical analysis, the differences in patient characteristics
between OCPs and non-OCPs groups were tested using the chi-
square test and t-test for category variables and continuous vari-
ables, respectively. Univariate and multivariate logistic regression
analyses were used to analyze the association between maternal
OCP use and allergic diseases in children. The potential con-
founders were included in multivariate models to obtain the
adjusted odds ratios (aORs). We also performed a trend test for
duration of OCP use with the logistic model by treating duration of
OCP, the ordered variable, as continuous variables. All associations
based on models were presented with odds ratios with 95% con-
ﬁdence intervals (CI). Statistical analyses were conducted using
SPSS Version 22.0 (IBM Corp. Armonk, NY, USA), with a P-value of
<0.05 deﬁned as being statistically signiﬁcant.
Results
We obtained the data of 980 childrenwithout missing variables.
The comparison of subjects analyzed in our study with those who
were excluded revealed that a difference only in parity (see
Table 2). Table 3-1 and Table 3-2 showed the characteristics of the
participants according to OCP users and duration of OCP users.
There were statistically signiﬁcant differences for maternal age at
pregnancy, number of previous live births, type of delivery and
child's gender and daycare attendance in background characteris-
tics between OCP use group and non-OCP use group. Of the chil-
dren, 28.2% had a history of ever wheeze and 15.9% had current
wheeze, and 14.6% had ever asthma and 10.2% had current asthma,
at ﬁve years old. Among the mothers, 13.8% had a past history of
OCP use and 6.2% used OCP for more than three months in total.
Table 4 showed the association of maternal OCP use before
pregnancy with childhood wheeze and allergic outcomes. In the
adjusted analysis, maternal OCP was associated with an increased
risk of ever wheeze (aOR, 1.62; 95% CI, 1.10e2.40), current wheeze
(aOR, 1.59; 95% CI, 1.01e2.50), ever asthma (aOR, 1.65; 95% CI,
1.02e2.65) and ever rhinitis (aOR, 1.90; 95% CI, 1.30e2.80).
Table 5 showed the association of OCP use duration before
pregnancy with childhood wheeze and allergic outcomes. In
adjusted analysis, a usage of OCP of more than three months sta-
tistically was associated with an increased risk of ever wheezeTable 2
Comparison between the characteristics of participants included in the analysis and
those of lost follow up.
Data used
for analysis
Data not used
for analysis
P
n N % n N %
Maternal characteristics
OCP use (yes) 135 980 13.8 65 475 13.7 0.962
Maternal history of allergy (yes) 547 980 55.8 227 417 54.4 0.653
Level of education
Middle school or high school 98 980 10 42 411 10.2 0.901
Body mass index at pregnancy
(S25)
46 980 4.7 27 480 5.6 0.443
Smoking during pregnancy 22 980 2.2 16 476 3.4 0.210
Maternal age at pregnancy (S35) 407 980 41.5 188 479 39.2 0.405
Number of previous live births
(S1)
424 980 43.3 263 479 54.9 <0.001
Caesarean section 216 980 22 104 475 21.9 0.950
Gender (Male) 500 980 51 261 480 54.4 0.228
Daycare (yes) 206 980 21 62 319 19.4 0.544
Weeks of gestation, median (IQR) 39 (38, 40) 39 (38, 40) 0.120y
y ManneWhitney test. IQR, Interquartile range25th, 75th.
Table 3-1
Characteristics of the participants according to OCP users.
OCP (no) OCP (yes) P
n ¼ 845 n ¼ 135
n % n %
Maternal history of allergy 0.292
Yes 466 55.1 81 60.0
No 379 44.9 54 40.0
Level of education 0.089
Middle school or high school 79 9.3 19 14.1
College, university or graduate school 766 90.7 116 85.9
Body mass index at pregnancy 0.771
<25 806 95.4 128 94.8
S25 39 4.6 7 5.2
Smoking during pregnancy (yes) 0.985y
Yes 19 2.2 3 2.2
No 826 97.8 132 97.8
Maternal age at pregnancy
(S35 years old)
0.009
<35 508 60.1 65 48.1
S35 337 39.9 70 51.9
Number of previous live births (S1) 0.02
0 467 55.3 89 65.9
S1 378 44.7 46 34.1
Type of delivery 0.012
Caesarean section 175 20.7 41 30.4
Vaginal delivery 670 79.3 94 69.6
Child's characteristics
Gender 0.001
Male 413 48.9 87 64.4
Female 432 51.1 48 35.6
Daycare 0.132
Yes 171 20.2 35 25.9
No 674 79.8 100 74.1
Weeks of gestation, median
(interquartile range25%, 75%)
39 (38, 40) 39 (38, 40) 0.201z
Allergy outcomes at 5 years old
Ever wheeze 223 16.4 53 39.3 0.002
Current wheeze 124 14.7 32 23.7 0.008
Ever asthma 115 13.6 28 20.7 0.029
Current asthma 80 9.5 20 14.8 0.057
Ever atopic dermatitis 206 24.4 30 22.2 0.586
Current atopic dermatitis 189 22.4 28 20.7 0.673
Ever rhinitis 301 35.6 70 51.9 <0.001
Current rhinitis 81 9.6 16 11.9 0.413
y Fisher exact test.
z ManneWhitney test.
Table 3-2
Characteristics of OCP users according to duration of OCP use.
OCP (no) OCP (yes) P
<3 months 3months
n ¼ 845 n ¼ 74 n ¼ 61
n % n % n %
Maternal history of allergy 0.561
Yes 466 55.1 45 60.8 36 59.0
No 379 44.9 29 39.2 25 41.0
Level of education 0.169
Middle school or high school 79 9.3 9 12.2 10 16.4
College, university or graduate
school
766 90.7 65 87.8 51 83.6
Body mass index at pregnancy 0.758
<25 806 95.4 71 95.9 57 93.4
S25 39 4.6 3 4.1 4 6.6
Smoking during pregnancy (yes) 0.787y
Yes 19 2.2 1 1.4 2 3.3
No 826 97.8 73 98.6 59 96.7
Maternal age at pregnancy
(S35 years old)
0.021
<35 508 60.1 33 44.6 32 52.5
S35 337 39.9 41 55.4 29 47.5
Number of previous live births
(S1)
0.042
0 467 55.3 46 62.2 43 70.5
S1 378 44.7 28 37.8 18 29.5
Type of delivery 0.035
Caesarean section 175 20.7 24 32.4 17 27.9
Vaginal delivery 670 79.3 50 67.6 44 72.1
Child's characteristics
Gender 0.003
Male 413 48.9 49 66.2 38 62.3
Female 432 51.1 25 33.8 23 37.7
Daycare 0.029
Yes 171 20.2 14 18.9 21 34.4
No 674 79.8 60 81.1 40 65.6
Weeks of gestation, median
(interquartile range25%, 75%)
39 (38, 40) 39 (38, 40) 39 (38, 40) 0.413z
Allergy outcomes at 5 years old
Ever wheeze 223 26.4 27 36.5 26 42.6 0.006
Current wheeze 124 14.7 16 21.6 16 26.2 0.022
Ever asthma 115 13.6 16 21.6 12 19.7 0.088
Current asthma 80 9.5 13 17.6 7 11.5 0.083
Ever atopic dermatitis 206 24.4 19 25.7 11 18 0.505
Current atopic dermatitis 189 22.4 17 23 11 18 0.722
Ever rhinitis 301 35.6 38 51.4 32 52.5 0.001
Current rhinitis 81 9.6 8 10.8 8 13.1 0.648
y Fisher exact test.
z KruskaleWallis test.
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(P ¼ 0.002) among ﬁve-year-old children compared to no OPC use
and 1 daye3 months OCP use.Discussion
Our results supported the hypothesis that maternal history of
OCP use before pregnancy is associated with increased respiratory
allergic disease signs in the ﬁrst ﬁve years of life. Moreover, longer
time use of OCP was associated with an increased risk of such
conditions. Strength of our study was the study design of which
evidence level is higher than trans-sectional case-control studies
ever reported. Especially this prospective birth cohort consisted of
general population not focusing on children with high risk of
allergy.
A Norwegian birth cohort study examined the inﬂuence of two
types of OCPs (estrogen-progestin combined pills and progestin-
only pills) and found that progestin-only pills use was slightly
associated with wheeze in children at 6e8 months old (aOR, 1.19;
95% CI, 1.05e1.34).9 Meanwhile, a Jamaican cohort study, not
evaluating the types of OCP, reported that maternal OCP use was
associated with asthma or wheeze in children at 11e12 years old(aOR, 1.81; 95% CI, 1.25e2.61).7 On the other hand, a German case-
control study, not evaluating the types of OCP as well, did not show
an association between OCP use and asthma/allergic rhinitis, but
showed an association with atopic eczema among children aged
5e14 years instead, as noted by Frye et al.12 Another case-control
study in the UK demonstrated that OCP use within 6 months of
conception was associated with asthma (aOR, 1.16; 95% CI,
1.06e1.27).8 As to the association between OCP use and allergic
outcomes of young adults, young women in German cohort study
had the inverse association between OCP use and new-onset
asthma and allergic rhinitis after puberty.13 Regarding hormone
replacement therapy, another cohort study reported that post-
menopausal women in the US who used hormones increased the
risk of asthma compared to thosewho never used.14 A controversial
impact of OCPs as well as hormone replacement therapy on
wheeze/allergy implies that the dose and type of OCP used and the
duration and timing of the usagemay inﬂuence the development of
wheeze and allergy in children and adults. Comparative study with
USA and France found OCP use was not the ﬁrst choice for
Table 4
Associations of OCP use before pregnancy with allergy outcomes in children at 5
years old.
Crude OR (95% CI) Adjusted OR (95% CI)y
OR Lower Upper P OR Lower Upper P
Ever wheeze 1.80 1.24 2.63 0.002 1.62 1.10 2.40 0.015
Current wheeze 1.81 1.16 2.81 0.008 1.59 1.01 2.50 0.046
Ever asthma 1.66 1.05 2.63 0.031 1.65 1.02 2.65 0.040
Current asthma 1.66 0.98 2.82 0.059 1.64 0.95 2.84 0.077
Ever atopic eczema 0.89 0.57 1.37 0.587 0.87 0.55 1.35 0.523
Current atopic eczema 0.91 0.58 1.42 0.673 0.88 0.56 1.39 0.593
Ever rhinitis 1.95 1.35 2.81 <0.001 1.90 1.30 2.80 0.001
Current rhinitis 1.27 0.72 2.24 0.414 1.07 0.60 1.94 0.813
y ORs adjusted for maternal history of allergy (asthma, atopic dermatitis, or
allergic rhinitis), maternal education level, maternal age at pregnancy, maternal
BMI, maternal smoking during pregnancy, mode of delivery, gestational age at de-
livery, previous live birth, day care and gender of child.
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inwestern countries was higher than that in non-western countries
according to the large scale international epidemiological study.16
The prevalence of OCP use in western countries was also much
higher than that in Japan.17 If the prevalence of OCP use inﬂuences
the prevalence of offspring's childhood asthma and allergic out-
comes, the more Japanese populations use OCP, the higher the
prevalence of wheeze and allergic diseases may be.
At present, the underlying mechanisms of wheeze and allergic
diseases development caused by OCPs are still unclear. A recentTable 5
Associations of OCP use before pregnancy with wheeze and allergy outcomes in
children at 5 years old.
Crude OR (95% CI) Adjusted OR (95% CI)y
OR Lower Upper P OR Lower Upper P
Ever wheeze
1 daye2 months 1.60 0.97 2.64 0.063 1.45 0.87 2.42 0.151
3 months 2.07 1.22 3.52 0.007 1.85 1.08 3.18 0.026
P trend 0.002 0.012
Current wheeze
1 daye2 months 1.60 0.89 2.88 0.114 1.41 0.78 2.57 0.258
3 months 2.07 1.13 3.77 0.018 1.82 0.98 3.38 0.058
P trend 0.007 0.035
Ever asthma
1 daye2 months 1.75 0.97 3.15 0.062 1.66 0.91 3.03 0.100
3 months 1.56 0.80 3.01 0.191 1.63 0.83 3.21 0.159
P trend 0.055 0.057
Current asthma
1 daye2 months 2.04 1.07 3.87 0.030 1.97 1.02 3.82 0.044
3 months 1.24 0.55 2.82 0.608 1.23 0.53 2.86 0.623
P trend 0.169 0.204
Ever atopic eczema
1 daye2 months 1.07 0.62 1.85 0.804 1.06 0.61 1.84 0.846
3 months 0.68 0.35 1.34 0.265 0.66 0.33 1.30 0.228
P trend 0.386 0.33
Current atopic eczema
1 daye2 months 1.04 0.59 1.82 0.905 1.01 0.57 1.80 0.969
3 months 0.76 0.39 1.50 0.432 0.74 0.37 1.46 0.381
P trend 0.526 0.454
Ever rhinitis
1 daye2 months 1.91 1.18 3.07 0.008 1.89 1.15 3.11 0.013
3 months 1.99 1.18 3.36 0.010 1.92 1.11 3.31 0.019
P trend 0.001 0.002
Current rhinitis
1 daye2 months 1.14 0.53 2.47 0.733 0.99 0.45 2.18 0.982
3 months 1.42 0.65 3.10 0.373 1.17 0.53 2.62 0.696
P trend 0.358 0.739
y ORs adjusted for maternal history of allergy (asthma, atopic dermatitis, or
allergic rhinitis), maternal education level, maternal age at pregnancy, maternal
BMI, maternal smoking during pregnancy, mode of delivery, gestational age at de-
livery, previous live birth, day care and gender of child.study revealed that an interaction among genetic variants in the
GATA 3, OCP use and DNA-methylation increased asthma preva-
lence in post-puberty women,18 suggesting that OCP use before
pregnancymay cause epigenetic changes such as DNA-methylation.
According to the Developmental Origins of Health and Disease
(DOHaD) theory,5,6,19 it is speculated these epigenetic alterations
before conception may be passed on to the embryo leading to the
development of wheeze and allergic diseases in their childhood
age, although there has been no evidence that preconceptional OCP
use had epigenetic inﬂuence on the gametocyte, so far. The
emerging concept of DOHaD hypothesis implies that an exposure of
the female gametocyte or the fetus to various environmental fac-
tors may contribute to the development of non-communicable
diseases in children. Besides preconceptional exposure to OCP,
prenatal exposure to acetaminophen was reported to be associated
with wheeze of children at age of 5 years.20 Exposures to various
medication not only during pregnancy but also even before
conception should be considered as candidates of risk factors to be
explored to prevent the development to childhood allergic
diseases.
There were several limitations in this study. We could not
evaluate the inﬂuence of different types of OCPs, because in Japan,
only estrogen-progestin pills were available to be prescribed
before and during the recruitment of pregnant women to this
birth cohort study. Furthermore, exact doses and timing of OCP
used by participants was impossible to be detected since enroll-
ment of participants for the birth cohort study was done after
conﬁrmed their pregnancy. Another limitation was that lost to
follow-up rate in this study was 35%, and the number of previous
live births was the only variable which showed statistical differ-
ence between subjects, but it gave no inﬂuence on our conclusion
even after adjustment. To minimize the inﬂuence of confounders,
a randomized controlled trials is the best to provide the highest
evidence, but they can not be permitted to be carried out from
ethical point of view to evaluate the risk of preconceptional OCP
use. One of the other limitations of our study was that we
measured childhood outcomes not directly by a physician but by a
questionnaire. Indeed, various birth cohort studies have used
validated questionnaires to evaluate outcomes. Single-center
recruitment in Tokyo was also the other limitation of our study.
Although participants in the cohort might not be representative of
whole Japanese population, we could found the statistically sig-
niﬁcant association between preconceptional OCP use and child-
hood wheeze and allergic outcomes after adjusting for the
confounders in our study.
In summary, our prospective birth cohort study suggested that
maternal OCP use was a risk of the development of childhood
wheeze and some allergic outcomes in their offspring. More than
three-months usage of OCP increased the risk of asthma and related
allergic outcomes.Acknowledgments
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